Sorafenib-Induced Severe Acute Hepatitis in a Stable Liver Transplant Recipient
Uta Herden,Lutz Fischer,Hansjörg Schäfer,Björn Nashan,Volker von Baehr,Martina Sterneck
DOI: https://doi.org/10.1097/tp.0b013e3181daac69
2010-01-01
Transplantation
Abstract:Sorafenib, an oral multikinase inhibitor, has been licensed as the first drug for the treatment of advanced hepatocellular cancer (HCC) based on a clear survival benefit shown in the Sorafenib HCC Assessment Randomized Protocol Trial (SHARP) study (1). Because of frequent multifocality and extrahepatic manifestations, therapy of recurrent HCC after liver transplantation is still a challenge. Sorafenib treatment could be a possible approach also in these patients, but little experience exists. However, recently, three cases of sorafenib-induced severe hepatitis were reported (2–4). Two of these patients suffered from underlying Child-Pugh A cirrhosis (2, 3). Herein, for the first time, we report a sorafenib- induced severe acute hepatitis in a liver transplant recipient with perfect graft function treated for only 5 days because of lung metastasis of recurrent HCC. CASE REPORT The 58-year-old man underwent liver transplantation for alcoholic liver cirrhosis and concomitant HCC (tumor classification pT3, pN0, V1, G2, R0). The postoperative course was uncomplicated, and the patient was discharged on the 19th postoperative day with excellent graft function. Immunosuppressive therapy included cyclosporine A and steroids. Four months after transplantation, HCC recurrence with multifocal pulmonary metastases occurred. At this time point, the patient still had a well-functioning graft with completely normal serum bilirubin and transaminases. Sorafenib therapy was initiated at a reduced dose of 200 mg twice daily. After 5 days of treatment, the patient presented to the emergency room with nausea, fever up to 39°C, and jaundice. Liver function test values showed a dramatic increase with aspartate aminotransferase 893 U/L (normal: 10–50 U/L), alanine aminotransferase 879 U/L (normal: 10–50 U/L), serum bilirubin 12 mg/dL, (normal: 0.2–1 U/L) γ-glutamyl transpeptidase 726 U/L (normal: 0–65 U/L), and C-reactive protein 25 mg/L (normal: 0–5 mg/L). Acute hepatitis A/B/C and cytomegalovirus and Epstein-Barr virus infection were ruled out by serologic tests. Likewise, other infectious foci were excluded by microbiologic and imaging tests. Ultrasonography showed normal liver parenchyma and good graft perfusion. Endoscopic retrograde cholangiography ruled out obstructive jaundice. Liver biopsy revealed centrolobular hepatocellular necroses and lymphoplasmacellular and granulocytic infiltration of the portal tracts with significant eosinophilia consistent with hyperallergic drug reactions (Fig. 1).FIGURE 1.: Histologic picture of the liver biopsy. Liver biopsy 5 days after onset of sorafenib treatment. The signs of toxic and hyperallergic drug reaction with focal intralobular hepatocellular necrosis (N) and mixed inflammatory infiltration containing eosinophilic granulocytes (arrows) in portal tracts (P). Inset: portal tract inflammation in higher magnification (hematoxylin-eosin).Because of these findings and the immediate onset after initiation of chemotherapy, sorafenib-induced hepatitis was suspected, and the medication was stopped. A lymphocyte transformation test subsequently performed revealed a significantly elevated stimulation index of 4.8 with sorafenib when compared with an unspecific stimulation indicating an immunoallergic drug reaction. After withdrawal of sorafenib, the patient's condition rapidly improved, and the level of liver enzymes decreased. Serum transaminases normalized within 2 weeks, and serum bilirubin level returned to baseline levels within 8 weeks. DISCUSSION To the best of our knowledge, this is the first case of drug-induced severe acute hepatitis in a patient treated with sorafenib after liver transplantation. Review of the literature showed two cases of sorafenib-induced hepatitis in a patient with Child-Pugh A cirrhosis because of nonalcoholic steatohepatitis (3) or hepatitis C infection with multinodular HCC (2), respectively. So far only one case of sorafenib-induced severe hepatitis in a patient without known liver disease or cirrhosis has been described (4). Most likely the incidence of severe hepatitis is less than 1% based on recent data (1, 5). The patient illustrated here had a perfect graft function and in addition no hepatic manifestation of his HCC. Therefore, we conclude that sorafenib carry a risk of acute hepatitis not only in patients with underlying liver cirrhosis but also in patients with normal liver function. This is in agreement with the idiosyncratic drug reaction, which we think is most likely responsible for the sorafenib-induced severe hepatitis of our patient. This assumption is based on the patient's clinical presentation with fever, the typical liver histology, and the positive lymphocyte stimulation test. In accordance with our findings, sorafenib-induced hepatitis was also diagnosed within 4 days to 8 weeks in the three previously described cases, and in addition, in one case, concomitant fever was mentioned (2–4). After cessation of sorafenib, one patient showed progression to liver failure and died for within 3 months (4), and all other patients quickly improved with or without additional steroid medication (2, 3). Therefore, the possibility of sorafenib- induced liver failure independent of prior liver disease should be taken into consideration, and liver parameters should be monitored regularly. In case of an increase of the liver enzymes, immediate cessation of treatment with sorafenib is mandatory. Uta Herden1 Lutz Fischer1 Hansjörg Schäfer2 Björn Nashan1 Volker von Baehr3 Martina Sterneck1 1 Department of Hepatobiliary Surgery and Solid Organ Transplantation University Medical Center Hamburg-Eppendorf Hamburg, Germany 2 Department of Pathology University Medical Center Hamburg-Eppendorf Hamburg, Germany 3 Institute of medical diagnostic Berlin, Germany